ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

Kodjikian, Laurent; Lecleire–Collet, A.; Dot, Corinne; Le Lez, Marie‐Laure; Baillif, Stéphanie; Erginay, Ali; H. Souied, Eric; Fourmaux, Eric; Gain, Philippe; Ponthieux, Anne

doi:10.2147/opth.s313081

Public

ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

Published in Clinical ophthalmology • Jun 1, 2021

Authors:

Laurent Kodjikian

A. Lecleire–Collet

Corinne Dot

Abstract

PURPOSE: To evaluate the real-world effectiveness of intravitreal ranibizumab 0.5 mg (Lucentis) in improving visual acuity (VA) in adults with decreased VA due to diabetic macular edema (DME). PATIENTS AND METHODS: Real-world prospective observational 24-month study. Ranibizumab-naïve patients (n=11...

Subject

Medicine

Ranibizumab

Diabetic macular edema

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!